Amantadine Hydrochloride Tablet
FDA Recall NDC 0832-0111

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

The FDA has identified 1 recorded enforcement report(s) associated with Amantadine Hydrochloride (NDC 0832-0111). A significant event, classified as Class II, was initiated on Mar 15, 2021 by Upsher-smith Laboratories, Llc. The reported reason for this action was: "CGMP Deviations: Intermittent exposure to temperature excursion during storage."

This specific recall has a current status of TERMINATED, indicating that the FDA considers the recall process finished or the product successfully recovered.

Reported Recall Events

March 2021 Class II Recall: CGMP Deviations

Recall Number
Class II Terminated
Reason for Recall
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Initiated
Mar 15, 2021
Reported
Jun 02, 2021
Quantity
271 bottles

Recall Profile & Regulatory Data

Event ID
87512
Classification
Class II
Enforcement Status
Terminated
Recalling Firm
Cardinal Health Inc.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
FL, GA, SC
Termination Date
Jun 17, 2024
Product Description
Amantadine Hydrochloride Tablets 100 mg 100-count bottle, Rx Only Manufactured by Upsher-Smith Laboratories, Inc. Maple Grove, MN 55369, NDC 0832-0111-00
Batch or Lot Expiration Information
Lot# 395310
Affected Packages Involved in this Recall
0832-0111-00Product
0832-0111-50Product
0832-0111-89Product
0832-0111-03Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.